Publications database

Steatotic liver diseases (SLDs), including metabolic dysfunction-associated steatotic liver disease (MASLD; formerly known as non-alcoholic fatty liver disease) and alcoholic liver disease, are the leading causes of chronic hepatitis, liver dysfunction, cirrhosis and liver cancer development. Severe manifestations of MASLD and alcoholic liver disease include metabolic dysfunction-associated steatohepatitis (MASH; formerly known as non-alcoholic steatohepatitis) and alcoholic steatohepatitis (ASH) or a combination thereof, termed metabolic dysfunction and alcohol-associated liver disease. [...]

Patient-derived in vitro systems are powerful preclinical models that replicate key features of human tumors and enable investigation of cancer biology and drug response. They are particularly promising for pancreatic cancer research. [...]

Lactate metabolism is a hallmark of cancer metabolic reprogramming, shaping tumor immunity and therapeutic resistance, yet clinically accessible and low-cost methods to assess intratumoral lactate activity remain limited.We curated a lactate-related 59-gene signature and characterized its biological and clinical relevance across TCGA, GEO, and single-cell RNA-seq datasets. By integrating multi-omic, spatial, and computational analyses, we linked lactate metabolism to the tumor microenvironment and developed a deep learning framework to infer lactate metabolic states directly from routine H&E whole-slide images.High lactate activity (LAC_H) was associated with enhanced tumor proliferation, suppressed immune infiltration, and poor response to both immunotherapy and radiotherapy in HNSCC. [...]